BioSpace News Archive

Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation virtual conference in Maryland. On Monday, October 5, Chief Executive Officer at Immunomic, Dr. Bill Hearl, will participate in a panel titled, “Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency” alongside Novavax’s President and CEO, Stanley Erck, and Emmes’ President, Anne Lindbl

Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology. This portfolio of small molecule autophagy modulators, targeting PI3K and VPS34, was discovered by Neuropore Therapies and characterized using its comprehensive platform of autophagy and lysosomal biogenesis cellular a

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in a fireside chat at the H.C. Wainwright 4th Annual NASH In

PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder rights plan, often referred to as a “poison pill,” is effective September 28, 2020. Shareholders are not required, nor do they need, to take any action becau

 Blue Mountain Quality Resources (“Blue Mountain”), a developer of enterprise asset management products and services for the Life Sciences industry, today announced that it has re

Program will leverage Ion Torrent Genexus System* and Oncomine Precision Assay* to advance precision medicine for lung cancer in Asia

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 CAR-T Cell therapy.

Guide Sensmart, a world leading manufacturer of infrared thermal imaging systems, has had its IR236 IR Fever Warning System added to the list of authorized medical devices for uses related to COVID-19 by Health Canada.

Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment of its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia.

Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved REBLOZYL® for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.